The Interleukin-2 (IL-2) Mutein Therapies Market Is Evolving Due To The Increasing Demand For Targeted Immunotherapies The Growth Of The Market Due To Advancements In Immune-Based Cancer Treatments

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Does The Market Size Of The Interleukin-2 (IL-2) Mutein Therapies Market Compare Between 2026 And 2030?

The interleukin-2 (il-2) mutein therapies market size has experienced rapid expansion in recent years. Its valuation is set to grow from $0.73 billion in 2025 to $0.84 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.1%. This historical growth can be linked to advancements in cytokine engineering techniques, a greater understanding of immune signaling pathways, initial clinical successes of modified IL-2 therapies, increased investment in immuno-oncology research, and the rising incidence of immune-mediated diseases.

The interleukin-2 (il-2) mutein therapies market is anticipated to experience swift expansion in the coming years, reaching $1.43 billion by 2030 with a compound annual growth rate (CAGR) of 14.4%. This projected growth throughout the forecast period stems from the broader adoption of personalized immunotherapy methods, an increase in clinical trial engagement for advanced cytokines, a heightened need for safer immune modulators, increasing regulatory backing for novel biologics, and a rise in collaborations between biotechnology and pharmaceutical firms. Significant developments expected during this period involve the intensified creation of receptor-biased il-2 muteins, a greater emphasis on reducing cytokine toxicity, wider application of combined immunotherapy protocols, the broadening of precise immune modulation strategies, and more robust clinical pipeline activities for both autoimmune and oncology treatments.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33185&type=smp

Which Key Factors Are Driving The Interleukin-2 (IL-2) Mutein Therapies Market Growth?

The rising need for targeted immunotherapies is anticipated to boost the growth of the interleukin-2 (IL-2) mutein therapies market. These therapies are designed to modify the immune system to specifically target cancer cells, reducing harm to healthy tissues. The demand for these treatments is increasing as healthcare professionals and researchers seek safer and more effective options compared to traditional chemotherapy and radiation, which often have significant side effects and limited precision. IL-2 mutein therapies advance targeted immunotherapies by using modified versions of interleukin-2 that selectively activate immune effector cells involved in fighting tumors, while minimizing the activation of pathways linked to widespread toxicity. For example, in April 2025, the Cancer Research Institute, a US-based non-profit organization, reported that FDA approvals included 17 new targeted immunotherapy agents in 2024, expanding choices for immune-based cancer treatment and increasing the number of eligible patients. Consequently, the increasing demand for targeted immunotherapies is propelling the growth of the interleukin-2 (IL-2) mutein therapies market.

Which Segment Categories Are Included In The Interleukin-2 (IL-2) Mutein Therapies Market Segment Analysis?

The interleukin-2 (il-2) mutein therapies market covered in this report is segmented –

1) By Product Type: Monotherapy; Combination Therapy

2) By Route Of Administration: Intravenous; Subcutaneous; Other Route Of Administrations

3) By Application: Cancer; Autoimmune Diseases; Infectious Diseases; Other Applications

4) By End User: Hospitals; Specialty Clinics; Research Institutes; Other End Users

Subsegments:

1) By Monotherapy: Single Agent Interleukin Two Mutein Therapy; Standalone Cytokine Based Immunotherapy; Targeted Immune Modulation Therapy

2) By Combination Therapy: Interleukin Two Mutein With Immune Checkpoint Inhibitors; Interleukin Two Mutein With Chemotherapy; Interleukin Two Mutein With Targeted Biologic Therapies; Interleukin Two Mutein With Cell Based Therapies

Which Trends Are Guiding The Direction Of The Interleukin-2 (IL-2) Mutein Therapies Market?

Leading companies within the interleukin-2 (IL-2) mutein therapies market are increasingly prioritizing technological progress in cytokine-based immunotherapy, specifically focusing on selective regulatory T-cell (Treg) activation achieved through engineered IL-2 muteins. This selective regulatory T-cell activation via engineered IL-2 muteins entails employing genetically modified IL-2 proteins crafted to preferentially stimulate Tregs while simultaneously limiting the activation of effector immune cells. For instance, in December 2023, Almirall S.A., a pharmaceutical company based in Spain, launched the inaugural Phase I clinical study for ALM223, its engineered IL-2 mutein fusion protein, to assess its safety, pharmacokinetics, immunogenicity, and pharmacodynamics in individuals with autoimmune diseases. This particular candidate exhibits selective Treg activation, incorporates a modified Fc fusion to enhance molecular stability, and features an engineered cytokine backbone designed to optimize immune modulation. While these technological advancements highlight the significant potential of IL-2 muteins in delivering targeted immunomodulation and offering broader applicability for autoimmune conditions, their clinical efficacy and long-term safety profiles must still be thoroughly established through current and upcoming trials.

Who Are The Active Companies Shaping The Interleukin-2 (IL-2) Mutein Therapies Market?

Major companies operating in the interleukin-2 (il-2) mutein therapies market are Merck & Co. Inc., Sanofi S.A., Roche Holding AG, Bristol-Myers Squibb, Amgen Inc., Lonza Group AG, Alkermes plc, BioNTech SE, Xencor Inc., Innovent Biologics Inc., Ascendis Pharma A/S, ShanghAI Junshi Biosciences Co. Ltd., Mural Oncology Inc., ProBioGen AG, Werewolf Therapeutics Ltd., Philogen S.p.A., Cue Biopharma Inc., Medicenna Therapeutics Corp., Bright Peak Therapeutics Inc., Iovance Biotherapeutics Inc.

Get The Full Interleukin-2 (IL-2) Mutein Therapies Market Report:

https://www.thebusinessresearchcompany.com/report/interleukin-2-il-2-mutein-therapies-market-report

Which Region Dominates The Interleukin-2 (IL-2) Mutein Therapies Market By Market Share?

North America was the largest region in the interleukin 2 (IL-2) mutein therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the interleukin-2 (il-2) mutein therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Interleukin-2 (IL-2) Mutein Therapies Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/customise?id=33185&type=smp

Browse Through More Reports Similar to the Global Interleukin-2 (IL-2) Mutein Therapies Market 2026, By The Business Research Company

Artificial Intelligence Ai Studio Market Report 2026

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-studio-global-market-report

Ai Content Marketing Market Report 2026

https://www.thebusinessresearchcompany.com/report/ai-content-marketing-global-market-report

Artificial Intelligence Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795